ADC Therapeutics (NYSE:ADCT) specializes in the development of antibody-drug conjugates (ADCs) for treating various types of cancers. With a focus on leveraging its proprietary technology to develop highly potent and targeted cancer therapies, ADC Therapeutics aims to revolutionize cancer treatment. Their pipeline includes several projects in various stages of clinical development, designed to address the unmet needs of cancer patients across a broad range of hematologic and solid tumors. The company's primary objective is to advance its lead candidates through clinical trials toward regulatory approval, while also exploring potential new therapeutic applications for its technology platform. Through rigorous research and innovation, ADC Therapeutics is committed to improving outcomes for patients facing challenging cancer diagnoses.